Update: 14.02.2021
Last week: 5 week 2022 (31.01.2022 - 6.02.2022)
Last full month: Jan 2021
| Time period | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat.Vol, Change |
|---|---|---|---|---|---|---|---|---|---|
| APILAC | |||||||||
| WoW | 2 713 | 1.0% | 53.5% | 2.4 | 1 205 523 | 2.3% | 81.1% | 1.4 | -3.5% |
| MoM | 9 905 | 26.3% | 51.5% | 5.7 | 4 344 704 | 26.7% | 79.8% | 4 | 12.3% |
| YTD | 11 943 | 4.7% | 52.3% | -6 | 5 255 769 | 33.2% | 80.4% | -0.5 | 16.7% |
| MAT | 118 146 | -22.7% | 55.0% | -6.6 | 46 921 296 | 2.1% | 80.2% | -0.7 | -13.5% |
| CAPSICAM | |||||||||
| WoW | 23 733 | -0.9% | 3.5% | 0.1 | 9 691 970 | -0.9% | 3.7% | 0.1 | -3.7% |
| MoM | 98 524 | -7.4% | 3.6% | -0.5 | 40 398 608 | -6.6% | 3.8% | -0.5 | 5.6% |
| YTD | 112 845 | -7.1% | 3.5% | -0.1 | 46 239 774 | -9.9% | 3.8% | -0.5 | -4.4% |
| MAT | 1 056 548 | -19.6% | 3.2% | -0.2 | 433 902 959 | -9.6% | 3.5% | -0.3 | -14.5% |
| MILDRONATE | |||||||||
| WoW | 117 710 | 7.3% | 22.2% | 1.5 | 52 154 488 | 13.7% | 20.2% | 2.1 | 0.1% |
| MoM | 430 377 | 3.2% | 21.8% | -0.7 | 175 100 313 | 7.9% | 19.0% | 0 | 6.5% |
| YTD | 510 184 | 12.3% | 16.7% | 0.7 | 211 604 342 | 7.5% | 15.2% | -0.3 | 7.6% |
| MAT | 4 851 388 | 10.3% | 17.3% | 2.9 | 1 948 233 240 | 13.1% | 15.4% | 2.2 | -8.2% |
| SULFARGIN | |||||||||
| WoW | 3 307 | -0.1% | 0.9% | 0 | 1 591 198 | -1.2% | 1.3% | 0 | -0.1% |
| MoM | 13 779 | -21.2% | 0.9% | -0.3 | 6 745 395 | -20.1% | 1.3% | -0.3 | 4.0% |
| YTD | 15 687 | 1.8% | 0.9% | 0.1 | 7 660 229 | 7.0% | 1.3% | 0.2 | -9.2% |
| MAT | 164 423 | -21.3% | 0.8% | -0.1 | 80 263 303 | -9.0% | 1.2% | 0 | -11.9% |
| VIPROSAL | |||||||||
| WoW | 31 816 | 2.9% | 4.7% | 0.3 | 12 534 912 | 3.0% | 4.8% | 0.3 | -3.7% |
| MoM | 121 819 | -11.4% | 4.4% | -0.8 | 48 011 965 | -11.8% | 4.6% | -0.9 | 4.8% |
| YTD | 141 829 | 33.1% | 4.4% | 1.3 | 55 834 917 | 34.9% | 4.6% | 1.1 | -6.0% |
| MAT | 1 278 785 | -8.8% | 3.8% | 0.2 | 485 727 991 | -0.6% | 3.9% | 0.1 | -13.5% |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat.Vol, Change |
|---|---|---|---|---|---|---|---|---|---|
| APILAC | 2 713 | 1.0% | 53.5% | 2.4 | 1 205 523 | 2.3% | 81.1% | 1.4 | -3.5% |
| CAPSICAM | 23 733 | -0.9% | 3.5% | 0.1 | 9 691 970 | -0.9% | 3.7% | 0.1 | -3.7% |
| MILDRONATE | 117 710 | 7.3% | 22.2% | 1.5 | 52 154 488 | 13.7% | 20.2% | 2.1 | 0.1% |
| SULFARGIN | 3 307 | -0.1% | 0.9% | 0 | 1 591 198 | -1.2% | 1.3% | 0 | -0.1% |
| VIPROSAL | 31 816 | 2.9% | 4.7% | 0.3 | 12 534 912 | 3.0% | 4.8% | 0.3 | -3.7% |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat.Vol, Change |
|---|---|---|---|---|---|---|---|---|---|
| APILAC | 9 905 | 26.3% | 51.5% | 5.7 | 4 344 704 | 26.7% | 79.8% | 4 | 12.3% |
| CAPSICAM | 98 524 | -7.4% | 3.6% | -0.5 | 40 398 608 | -6.6% | 3.8% | -0.5 | 5.6% |
| MILDRONATE | 430 377 | 3.2% | 21.8% | -0.7 | 175 100 313 | 7.9% | 19.0% | 0 | 6.5% |
| SULFARGIN | 13 779 | -21.2% | 0.9% | -0.3 | 6 745 395 | -20.1% | 1.3% | -0.3 | 4.0% |
| VIPROSAL | 121 819 | -11.4% | 4.4% | -0.8 | 48 011 965 | -11.8% | 4.6% | -0.9 | 4.8% |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat.Vol, Change |
|---|---|---|---|---|---|---|---|---|---|
| APILAC | 11 943 | 4.7% | 52.3% | -6 | 5 255 769 | 33.2% | 80.4% | -0.5 | 16.7% |
| CAPSICAM | 112 845 | -7.1% | 3.5% | -0.1 | 46 239 774 | -9.9% | 3.8% | -0.5 | -4.4% |
| MILDRONATE | 510 184 | 12.3% | 16.7% | 0.7 | 211 604 342 | 7.5% | 15.2% | -0.3 | 7.6% |
| SULFARGIN | 15 687 | 1.8% | 0.9% | 0.1 | 7 660 229 | 7.0% | 1.3% | 0.2 | -9.2% |
| VIPROSAL | 141 829 | 33.1% | 4.4% | 1.3 | 55 834 917 | 34.9% | 4.6% | 1.1 | -6.0% |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat.Vol, Change |
|---|---|---|---|---|---|---|---|---|---|
| APILAC | 118 146 | -22.7% | 55.0% | -6.6 | 46 921 296 | 2.1% | 80.2% | -0.7 | -13.5% |
| CAPSICAM | 1 056 548 | -19.6% | 3.2% | -0.2 | 433 902 959 | -9.6% | 3.5% | -0.3 | -14.5% |
| MILDRONATE | 4 851 388 | 10.3% | 17.3% | 2.9 | 1 948 233 240 | 13.1% | 15.4% | 2.2 | -8.2% |
| SULFARGIN | 164 423 | -21.3% | 0.8% | -0.1 | 80 263 303 | -9.0% | 1.2% | 0 | -11.9% |
| VIPROSAL | 1 278 785 | -8.8% | 3.8% | 0.2 | 485 727 991 | -0.6% | 3.9% | 0.1 | -13.5% |
## [1] "VIPROSAL"## [1] "VIPROSAL B UNGUENT FOR EXT USE 30 G #1"## [1] "VIPROSAL B UNGUENT FOR EXT USE 50 G #1"## [1] "VIPROSAL B UNGUENT FOR EXT USE 75 G #1"## [1] "VIPROSAL"## [1] "VIPROSAL B UNGUENT FOR EXT USE 30 G #1"## [1] "VIPROSAL B UNGUENT FOR EXT USE 50 G #1"## [1] "VIPROSAL B UNGUENT FOR EXT USE 75 G #1"## [1] "CAPSICAM"## [1] "CAPSICAM UNGUENT FOR EXT USE 30 G #1"## [1] "CAPSICAM UNGUENT FOR EXT USE 50 G #1"## [1] "CAPSICAM"## [1] "CAPSICAM UNGUENT FOR EXT USE 30 G #1"## [1] "CAPSICAM UNGUENT FOR EXT USE 50 G #1"## [1] "MILDRONATE"## [1] "MILDRONATE CAPS 250 MG #40"## [1] "MILDRONATE CAPS 500 MG #60"## [1] "MILDRONATE"## [1] "MILDRONATE CAPS 250 MG #40"## [1] "MILDRONATE CAPS 500 MG #60"## [1] "SULFARGIN"## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 15 G #1"## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 50 G #1"## [1] "SULFARGIN"## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 15 G #1"## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 50 G #1"## [1] "APILAC"## [1] "APILAC TABS 10 MG #25"## [1] "APILAC TABS 10 MG #50"## [1] "APILAC"## [1] "APILAC TABS 10 MG #25"## [1] "APILAC TABS 10 MG #50"Abbreviations
WoW - Week Over Week Change = Sales of the last week / Sales of the previous week - 1
MoM - Month Over Month Change = Sales of the last full month / Sales of the previous full month - 1
YTD - Year to Date - a period of time beginning the first day of the current calendar year up to the current date
MAT - Moving Annual Total - a period, being any 12 month period ending on the last week
MS - Market Share
Data Sources:
DSM: Sales
Palomars: TRPs
MI: Fact Digital Costs
MI Estimated Costs: TV costs